Retaking sleeping sickness control in Angola

被引:29
作者
Abel, PM
Kiala, G
Lôa, V
Behrend, M
Musolf, J
Fleishmann, H
Théophile, J
Krishna, S
Stich, A
机构
[1] Med Mission Inst, Dept Trop Med & Epidem Control, D-97074 Wurzburg, Germany
[2] ANGOTRIP, Caritas Angola, Bairro Rocha Pinto, Luanda, Angola
[3] Inst Combate & Controlo Tripanossomiase, Luanda, Angola
[4] St George Hosp, Sch Med, Dept Infect Dis, London SW17 0RE, England
关键词
Angola; human African trypanosomiasis; sleeping sickness; Trypanosoma brucei gambiense;
D O I
10.1046/j.1365-3156.2003.01152.x
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Africa is severely affected by a resurgence of human African trypanosomiasis (HAT) at epidemic proportions. We report the results of the first 5 years of a HAT control programme in northern Angola run by the non-governmental organization (NGO) ANGOTRIP. In the period between 1996 and 2001, 13 426 patients were screened for HAT. The mortality rate of patients in stage 11 who were treated with melarsoprol fell from 7.5% to 2.9%, possibly as a result of training and the standardization of treatment protocols. A total of 191 578 people in three provinces of Angola were screened for HAT. Vector control activities were initiated using Lancien traps. Our experiences reflect the connection between war and the increasing incidence of disease, but also demonstrate that HAT control is possible by dedicated NGOs in close cooperation with national institutions even under extremely difficult circumstances.
引用
收藏
页码:141 / 148
页数:8
相关论文
共 16 条
[1]   Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense:: a randomised trial [J].
Burri, C ;
Nkunhu, S ;
Merolle, A ;
Smith, T ;
Blum, J ;
Brun, R .
LANCET, 2000, 355 (9213) :1419-1425
[2]   Pharmacokinetic investigations in patients from northern Angola refractory to melarsoprol treatment [J].
Burri, C ;
Keiser, J .
TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2001, 6 (05) :412-420
[3]  
BUXTON PA, 1955, P ROY ENT SOC LONDON, V19, P71
[4]  
Dumas M, 2000, B WORLD HEALTH ORGAN, V78, P1474
[5]  
JOSENANDO T, 1994, MANUAL REGRAS CONTRO
[6]  
LAVEISSIERE C, 1990, APPROPRIATE TECHNOLO
[7]   Treatment of human African trypanosomiasis -: present situation and needs for research and development [J].
Legros, D ;
Ollivier, G ;
Gastellu-Etchegorry, M ;
Paquet, C ;
Burri, C ;
Jannin, J ;
Büscher, P .
LANCET INFECTIOUS DISEASES, 2002, 2 (07) :437-440
[8]   RISK-FACTORS FOR ENCEPHALOPATHY AND MORTALITY DURING MELARSOPROL TREATMENT OF TRYPANOSOMA-BRUCEI-GAMBIENSE SLEEPING SICKNESS [J].
PEPIN, J ;
MILORD, F ;
KHONDE, AN ;
NIYONSENGA, T ;
LOKO, L ;
MPIA, B ;
DEWALS, P .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1995, 89 (01) :92-97
[9]  
SIMARRO PP, 1999, TROP MED INT HEALTH, V12, P585
[10]  
Smith DH, 1998, BRIT MED BULL, V54, P341, DOI 10.1093/oxfordjournals.bmb.a011692